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Abstract 
Background: Poly(ADP‑ribose) polymerase 1 (PARP‑1), which catalyzes poly(ADP‑ribosyl)ation of proteins by using 
NAD+ as a substrate, plays a key role in several nuclear events, including DNA repair, replication, and transcription. 
Recently, PARP‑1 was reported to participate in the somatic cell reprogramming process. Previously, we revealed a role 
for PARP‑1 in the induction of neural apoptosis in a cellular model of cerebral ischemia and suggested the possible 
use of PARP inhibitors as a new therapeutic intervention. In the present study, we examined the effects of PARP inhibi‑
tors on neural stem/progenitor cells (NSPCs) of the mouse brain.
Results: PARP‑1 was more abundant and demonstrated higher activity in NSPCs than in mouse embryonic fibro‑
blasts. Treatment with PARP inhibitors suppressed the formation of neurospheres by NSPCs through the suppression 
of cell cycle progression and the induction of apoptosis. In order to identify the genes responsible for these effects, 
we investigated gene expression profiles by microarray analyses and found that several genes in the p53 signaling 
pathway were upregulated, including Cdkn1a, which is critical for cell cycle control, and Fas, Pidd, Pmaip1, and Bbc3, 
which are principal factors in the apoptosis pathway. Inhibition of poly(ADP‑ribosyl)ation increased the levels of p53 
protein, but not p53 mRNA, and enhanced the phosphorylation of p53 at Ser18. Experiments with specific inhibitors 
and also shRNA demonstrated that PARP‑1, but not PARP‑2, has a role in the regulation of p53. The effects of PARP 
inhibitors on NSPCs were not observed in Trp53−/− NSPCs, suggesting a key role for p53 in these events.
Conclusions: On the basis of the finding that PARP inhibitors facilitated the p53 signaling pathway, we propose that 
poly(ADP‑ribosyl)ation contributes to the proliferation and self‑renewal of NSPCs through the suppression of p53 
activation.
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Apoptosis
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 
belong to the PARP family, which consists of 17 pre-
dicted members that share a catalytic domain homolo-
gous to that of PARP-1 [1, 2]. These enzymes use NAD+ 
as a substrate, synthesize ADP-ribose molecules, and 
transfer them onto the glutamate, aspartate, or lysine 
residues of acceptor proteins. Poly(ADP-ribosyl)ation 
regulates nuclear functions and responses that include 
DNA repair, replication, transcription, and chromatin 
modification. After exposure to genotoxic chemicals, 
such as DNA alkylating agents, PARP-1 binds to the 
DNA strand breaks, resulting in a change of conforma-
tion and increase of its enzymatic activity by 10–500 fold 
[3–5]. The modified acceptor proteins, including histones 
and PARP-1 itself, greatly change their size by harboring 
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up to several hundred ADP-ribose residues [2, 6]. The 
polyanionic structure thus formed counteracts the inhib-
itory effect of histones on DNA ligase. Conversely, exces-
sive activation of PARP-1 and depletion of NAD+ after 
severe DNA damage cause cell death by ATP depletion 
or an “energy crisis” [7, 8]. Previously, we reported a prin-
cipal role for PARP-1 in the induction of mitochondrial 
impairment that ultimately leads to neuronal apoptosis 
after cerebral ischemia [9], indicating that PARP inhibi-
tors could be a good therapeutic intervention for cerebral 
infarction.
PARP inhibitors such as 3-aminobenzamide (3AB) 
interact with the nicotinamide pocket of PARP-1, which 
is a highly conserved region in the catalytic domain of 
PARPs, and act as competitors of NAD+ [10, 11]. There-
fore, these inhibitors can suppress the activity of vari-
ous PARPs with a homogeneous catalytic domain. More 
recently, however, several PARP inhibitors selective for 
PARP-1 or PARP-2 have been developed to study their 
specific function or potential therapeutic application 
[12]. As little is known about the effects of PARP inhibi-
tors on somatic stem cells, these effects should be taken 
into consideration, particularly for their clinical use.
In the adult human and rodent brain, neural stem/pro-
genitor cells (NSPCs) exist in the subventricular zone of 
the lateral ventricles and propagate to the olfactory bulb 
[13, 14]. NSPCs are also present in the subgranular zone 
of the hippocampal dentate gyrus and possibly contribute 
to spatial memory formation and cognition [15]. In these 
regions, neurogenesis occurs even in physiological condi-
tions. However, under various types of brain injury, such 
as stroke, epileptic seizures, and trauma, the generation 
and proliferation of neural precursor cells are induced 
both in the subgranular and subventricular zones. The 
majority of neurons generated in the subventricular zone 
migrate toward the lesion site to replace damaged neu-
rons and induce neural regeneration [16].
Mutation of the p53 gene is observed frequently in 
cancer [17]. The function of p53 as a tumor suppressor 
depends principally on its ability to suppress cellular 
proliferation that would otherwise form tumor tissue. 
Activation of p53 induces cell cycle arrest and apopto-
sis [18, 19]. These functions of p53 result from its role 
as a transcription factor [20, 21]. Among the identified 
p53-target genes, p21 plays a critical role in the induc-
tion of cell cycle arrest [22, 23]. p21 is a cyclin-depend-
ent kinase inhibitor that induces both the G1 and G2 cell 
cycle arrest observed after p53 activation [24–26]. Con-
versely, p53 induces apoptosis by activating some genes 
that participate in the apoptotic response. Furthermore, 
p53 plays a critical role in preventing the reprogram-
ming of cells carrying various types of DNA damage [27]. 
Silencing of p53 significantly enhances the efficiency of 
the reprogramming of human somatic cells [28].
In the present study, we investigated the effects of 
PARP inhibitors on NSPCs in the adult brain and found 
two different effects, i.e., suppression of cell cycle pro-
gression and induction of apoptosis. Interestingly, both 
effects are mediated by the activation of p53. It is wor-
thy of special mention that more poly(ADP-ribosyl)ated 
proteins existed in NSPCs than in mouse embryonic 
fibroblasts (MEFs). On the basis of these results, PARP, 
or poly(ADP-ribosyl)ation, could play a principal role in 
the maintenance of NSPC multipotency through the sup-
pression of p53 function.
Methods
Separation and passage of NSPCs
All experimental protocols conformed to the Fundamen-
tal Guidelines for Proper Conduct of Animal Experiment 
and Related Activities in Academic Research Institu-
tions under the jurisdiction of the Ministry of Education, 
Culture, Sports, Science, and Technology, Japan, and 
all experiments were approved by the Animal Experi-
ment Committee of Osaka Ohtani University (No. 1012). 
NSPCs were obtained from Slc:ICR mouse embryos 
(embryonic day 13.5) as described previously [29–31]. 
The cells were dissociated and suspended at a density of 
2.0 × 106 cells in 100-mm dishes in 1× Dulbecco’s modi-
fied Eagle’s medium (DMEM)/F-12 neurosphere medium 
supplemented with B-27 (Gibco), 20  ng/mL human 
recombinant epidermal growth factor (EGF) (PeproTech), 
and 20 ng/mL human recombinant fibroblast growth fac-
tor (FGF)-basic (PeproTech). The culture medium was 
changed every other day and the cells were dissociated 
by using StemPro Accutase (Life Technologies) every 
4  days. The cells were passaged 3–5 times. Untreated 
bacterial-grade culture dishes were used for suspension 
cultures, whereas dishes coated with poly-l-ornithine and 
fibronectin were used for monolayer cultures.
Trp53 deficient mice
Trp53-heterozygous mice (accession no. CDB0001K) [32] 
were obtained from the RIKEN BioResource Center. Gen-
otyping for the Trp53 allele was performed by polymerase 
chain reaction (PCR) with primer 1 (5′-gttatgcatccatacag 
taca-3′) and primer 2 (5′-caggatatcttctggaggaag-3′).
PARP inhibitors
N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimeth-
ylacetamide (PJ34; Calbiochem), 1,5-isoquinolinediol 
(DHIQ; Santa Cruz Biotechnology), 3AB (Sigma), 
DR2313 (Wako Chemical), and UPF1069 (Wako Chemi-
cal) were used as PARP inhibitors.
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Immunocytochemistry
NSPCs were seeded at 5.0 × 104 cells per well in 8-well 
poly-l-ornithine- and fibronectin-coated Lab-Tek II 
Chamber Slides (Nalge Nunc). They were incubated for 
6 days with or without 20 μM PJ34 and the medium was 
changed every other day. Conversely, cells for the positive 
controls of neurons, astrocytes, and oligodendrocytes 
were incubated for 1 day in neural stem cell medium and 
then the medium was changed to 1× DMEM/F-12 sup-
plemented with B-27 for differentiation and incubated 
for 6 days. The cells were fixed in acetone/methanol for 
2  min. The antibodies to detect the following antigens 
were used for immunocytochemistry: nestin (sc-20978, 
1:25; Santa Cruz Biotechnology or MAB353, 1:200; 
Chemicon), beta-III tubulin (MAB1195, 1:100; R&D Sys-
tems), GFAP (Z0334, 1:500; Dako Cytomation), CNPase 
(MAB326, 1:200; Chemicon), p21 (sc-53870, 1:100; Santa 
Cruz Biotechnology), p53 (2524, 1:100; Cell Signaling), 
and phospho-p53 (Ser18) (9284, 1:50; Cell Signaling). 
Alexa Fluor dye-conjugated secondary antibodies of 
donkey anti-mouse IgG-Alexa Fluor 488 (A21202, 1:500; 
Molecular Probes) and goat anti-rabbit IgG-Alexa Fluor 
568 (A11036, 1:500; Molecular Probes) were used for 
detection. Nuclear staining was performed using 1 nM 4′, 
6-diamidino-2-phenylindole (17514; ABD Bioquest). Cel-
lular fluorescence images were acquired using a confocal 
laser scanning microscope (LSM 510; Carl Zeiss).
MTS assay
NSPCs were seeded at 1.0  ×  104 cells per well in 
96-well microplates coated with poly-l-ornithine and 
fibronectin. For 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium, inner salt (MTS) assay, a CellTiter 96 AQueous One 
Solution Cell Proliferation Assay kit (Promega) was used 
following the manufacturer’s instruction. Briefly, at 1  h 
before each of the desired time points, 20 µL MTS rea-
gent were added to each well and the cells were incubated 
at 37  °C for 1  h. Absorbance was detected at 490  nm 
using a Microplate Reader (Model 680; Bio-Rad). All 
experiments were repeated 3 times.
Gene expression profiling and data processing
Total RNA was extracted from NSPCs with or without 
treatment with 20  μM PJ34 by using an RNeasy Plus 
Mini Kit (QIAGEN). Microarray hybridizations were 
performed at Hokkaido System Science Co., Ltd. accord-
ing to the manufacturer’s protocol using the workflow 
for Agilent SurePrint G3 Mouse GE (8 × 60 K) microar-
rays. Each total RNA was prepared independently twice 
and analyzed for 2 biological replicates. These data were 
deposited in the Gene Expression Omnibus (GEO) at 
NCBI (www.ncbi.nlm.nih.gov/geo/) (accession number 
GSE69038). Differential expression analysis was per-
formed using the limma package [33]. A linear model 
was fitted to each gene, and empirical Bayes moderated 
t-statistics were used to assess differences in expression. 
The false discovery rate (FDR) adjusted p value was esti-
mated using the Storey’s q-value method [34], and sta-
tistical significance for differential expression was set to 
q value <0.05 and p value <0.05, coupled with a minimal 
difference of absolute fold change >2. Genes reaching sta-
tistical significance were mapped on pathways by using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) 
database [35]. The number of genes in each KEGG path-
way category was counted using the KEGG Orthology 
(KO) identifier. Subsequently, significantly enriched 
KEGG pathway categories were extracted based on p 
value <0.0001 and q value <0.01 by Fisher’s exact test, 
which was performed by using R (http://www.r-project.
org/).
Total RNA preparation and RT‑PCR
Cells rinsed with phosphate-buffered saline (PBS) were 
treated with a NucleoSpin RNA Plus Kit (Macherey–
Nagel). Total RNA was isolated according to the manu-
facturer’s protocol. RNA concentration was determined 
by measurement of A260. cDNA was made from total 
RNA using a ReverTra Ace Kit (Toyobo) with 0.5 μg total 
RNA per 25-μL reaction following the manufacturer’s 
instructions. Quantitative PCR for gene expression was 
performed with 2  μL diluted cDNA using KAPA SYBR 
Fast qPCR Master Mix (KAPA Biosystems) with spe-
cific primers (500 nM) in a total reaction volume of 5 μL. 
CFX96 Touch Real-time PCR System and CFX Manager 
software V3.1 (Bio-Rad Laboratories) were used to col-
lect and analyze data. Three replicates of each sample 
were amplified. Relative quantitation of RNA levels was 
determined by comparative CT reactions (ΔΔCT analy-
sis). Primers for the amplification of mouse Parp1, Parp2, 
and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 
(Table  1) were used. Gapdh served as the endogenous 
control. The quantity of target mRNA in each knock-
down cell was expressed in arbitrary units (relative 
quantitation).
Suppression of gene expression by shRNA
Parp-knockdown (KD) and pLKO.1 empty vectors for 
short hairpin RNA (shRNA)-expressing lentivirus were 
purchased from Open Biosystems. The RNAi consor-
tium (TRC) numbers were as follows: TRCN0000071211 
(Parp1-KD) and TRCN0000071216 (Parp2-KD). Lentivi-
rus was produced by transient transfection of 293T cells 
using a Trans-Lentiviral shRNA Packaging Kit (Thermo 
Fisher Scientific). The virus supernatant was concen-
trated by using a Lenti-X™ Concentrator (Takara Bio). 
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For virus infection, NSPCs were incubated with the con-
centrated virus supernatant in a 6-well plate and centri-
fuged at 1200×g for 1 h at 32 °C. The virus medium was 
removed at 6  h after infection and replaced with fresh 
medium. The infected cells were selected with 800  ng/
mL puromycin at 2 days after infection. Incubation was 
continued for an additional 2  days. Silencing was then 
assessed by measuring the levels of Parp1 and Parp2 
mRNA using RT-PCR.
Western blot analysis
NSPCs (2.0  ×  106 cells) were seeded in 100-mm dishes 
containing the PARP inhibitors or vehicle for 24 h. Scraped 
cells were collected and added to a sample buffer solu-
tion containing 2-mercaptoethanol (2×) for SDS-PAGE 
(Nacalai Tesque) and incubated at 95  °C for 5  min. Pro-
teins were separated using Mini-PROTEAN TGX gels 
(Bio-Rad), transferred with the Trans-Blot Turbo system 
(Bio-Rad), and detected with antibodies against the fol-
lowing proteins: beta-actin (A1978, 1:100,000; Sigma), 
p21 (sc-53870, 1:1000; Santa Cruz Biotechnology), p53 
(2524, 1:10,000; Cell Signaling), phospho-p53 (Ser18) 
(9284, 1:1000; Cell Signaling), cleaved caspase-3 (Asp175) 
(9661, 1:1000; Cell Signaling), cleaved caspase-8 (Asp387) 
(9429, 1:1000; Cell Signaling), caspase-9 (9504, 1:1000; 
Cell Signaling), poly(ADP-ribose) (4336-BPC-100, 1:5000; 
Trevigen), PARP-1 (MCA1522G, 1:5000; Serotec), ataxia 
telangiectasia mutated (ATM) (ab2618, 1:5000; Abcam), 
and ataxia telangiectasia and Rad3-related (ATR) (sc-1887, 
1:5000; Santa Cruz Biotechnology). A peroxidase-linked 
secondary antibody (NA931V, 1:1000; GE Healthcare) 
was used for detection. Antibody-antigen complexes were 
visualized by ImmunoStar LD (Wako). The chemilumines-
cent blots were imaged with a ChemiDoc XRS +  imager 
(Bio-Rad) and analyzed by ImageLab software version 
2.0.1 (Bio-Rad). All antibodies were distilled in HIKARI 
signal enhancer (Nacalai Tesque). For caspase activation, 
as a positive control, the cells were treated with 10  ng/
mL cycloheximide (Cell Signaling) for 24 h and 50 ng/mL 
mouse tumor necrosis factor-α (Cell Signaling) for 6 h.
Cell cycle analysis
The cells were synchronized by the double-thymidine-
block method as described previously, with minor modi-
fications [36, 37]. 2.0 ×  106 cells were seeded in twenty 
five 100 mm plates. One plate was used for time 0 (pre-
treatment). One set of 12 plates was used for PJ34 treat-
ment, and another set of 12 plates was used for control. 
They were subjected to the first treatment with 2  mM 
thymidine (Sigma) for 14  h, and then incubated in thy-
midine-free medium for 12  h, followed by the second 
treatment with 2  mM thymidine for 14  h to arrest the 
cell cycle at the G1/S boundary. The cells were washed 
twice with 1× DMEM/F-12 and then incubated in neu-
rosphere medium and analyzed every 2 h. The nuclei of 
the treated cells were collected and stained with propid-
ium iodide using a Cell Cycle TEST-PLUS DNA Staining 
Kit according to the manufacturer’s instructions (Bec-
ton–Dickinson). The DNA content of the stained nuclei 
was measured using a FACSCalibur Flow Cytometer 
(Becton–Dickinson). The results were analyzed by using 
ModFit LT 3.0 software (Verity Software House).
Flow cytometric analysis of cell death
After incubation with 20 μM PJ34 for 24 h, the cells were 
collected by low-speed centrifugation, washed with ice-
cold PBS, and resuspended in Annexin-V Binding Buffer 
(Becton–Dickinson). To detect Annexin-V-positive cells, 
the cells were incubated with Annexin-V (Becton–Dick-
inson) and 7-AAD (Becton–Dickinson) for 15  min at 
Table 1 Primer sequences for RT-PCR gene expression analysis
Gene Sense primer (5′–3′) Anti‑sense primer (5′–3′) Cycles Product (bp)
Parp1 TCGATGGGAAAGTCCCACAC CATTCTGAGCCTTGAGGGCC 28 600
Parp2 GACAATCGAGACTCTGTGAA AGACTGGTAACCGGCCTTGA 28 600
Gapdh ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 28 452
Cdkn1a GTGATTGCGATGCGCTCATG TCTCTTGCAGAAGACCAATC 26 387
Fas ATGCTGTGGATCTGGGCTGT GTTTTCAGGTTGGCATGGTT 28 190
Pidd ATGGCTGCAGTGTTGGAGGG CTCTGAGAGATGGTTGTGAG 28 500
Tnfrsf10b ATGGAGCCTCCAGGACCCAG GAGCTCCAATCAGCAGCACT 28 643
Pmaip1 ATGCCCGGGAGAAAGGCGCG GGTTACTAAATTGAAGAGCT 28 308
Bbc3 CCTCAGCCCTCCCTGTCACCAG GGGTGAGGGTCGGTGTCGAT 35 232
Perp ATGCTGCGCTGCGGCCTGGC GGAACAACCAATCAAGATGA 28 500
Ccng1 ATGATAGAAGTACTGACAAC GGTGTCGTGAACGAGTGAAT 24 500
Trp53 GGAGACATTTTCAGGCTTATGG AGAAGGGACAAAAGATGACAGG 28 232
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room temperature. The cells were analyzed with a FACS-
Calibur Flow Cytometer (Becton–Dickinson).
Chromatin staining for the detection of apoptosis
NSPCs were incubated with or without the PARP inhibi-
tors on poly-l-ornithine/fibronectin-coated Lab-Tek II 
Chamber Slides (Nalge Nunc) for 24  h. The cells were 
fixed with 4% paraformaldehyde in PBS for 10 min, fol-
lowed by chromatin staining with 1  μg/mL Hoechst 
33258 (Sigma) to detect morphological changes of nuclei 
associated with apoptosis.
Precipitation of poly(ADP‑ribosyl)ated proteins
Poly(ADP-ribosyl)ated proteins were isolated by using a 
highly specific Af1521 Macrodomain Poly(ADP-ribose) 
Affinity Resin Set (Tulip Biolabs). NSPCs were incu-
bated with or without 20 μM PJ34 for 24 h. Proteins were 
extracted from 4.0 × 106 cells using a lysis buffer (RIPA 
Buffer; Nacalai Tesque) and incubated with the affin-
ity resin overnight at 4  °C. The resin-bound proteins 
were dissociated from the affinity resin by incubation in 
SDS-sample buffer at 95  °C for 10 min and analyzed by 
immunoblotting.
Immunoprecipitation
NSPCs were incubated with or without 20  μM PJ34 for 
24  h. Cell lysates were prepared from 4.0  ×  106 cells 
using RIPA buffer (Nacalai Tesque). An antibody against 
p53 (2524, 1:500; Cell Signaling), ATM (ab2618, 1:500; 
Abcam), or ATR (sc-1887, 1:500; Santa Cruz Biotech-
nology) was added to the cell lysates, and μMACS Pro-
tein A/G MicroBeads (Miltenyi Biotec) were added to 
magnetically label the immune complexes. Magnetically 
labeled proteins were collected by using μ Columns and 
μMACS Separator (Miltenyi Biotec), and analyzed by 
immunoblotting.
Statistical analysis
The data were expressed as the mean value ±  standard 
error of the mean (SEM). We used one-way ANOVA fol-
lowed by Tukey’s post hoc test to analyze the differences 
among the three or more groups, and used Student’s t 
test for the differences between the two groups. Results 
were considered statistically significant at p < 0.05.
Results
Suppression of neurosphere formation by PARP inhibitors
NSPCs from the mouse brain were incubated with or 
without the PARP inhibitors (3AB, DHIQ, or PJ34). Neu-
rospheres were generated in the absence of the PARP 
inhibitors after incubation for 2  days, while neurosphere 
formation was suppressed by the PARP inhibitors in a con-
centration-dependent manner. Neurospheres were almost 
absent with 15 mM 3AB, 200 μM DHIQ, or 20 μM PJ34 
(Fig.  1a). The concentrations of the 3 inhibitors required 
for these biological effects on NSPCs corresponded to their 
half maximal (50%) inhibitory concentrations (IC50s): 
IC50s of 3AB, DHIQ, and PJ34 were 33 μM, 390 nM, and 
20 nM, respectively [38, 39]. An approximately 1000-fold 
higher concentration of the inhibitors, as compared with 
their IC50s, effectively suppressed neurosphere forma-
tion by NSPCs. We then evaluated the viability of NSPCs 
by measuring MTS-reducing activity, which was increased 
by 2.6-fold after culture for 2  days in the absence of the 
PARP inhibitors (Fig.  1b). This increase was significantly 
suppressed by the addition of the PARP inhibitors (3AB, 
DHIQ, or PJ34), indicating that exposure to the PARP 
inhibitors damages the viability of NSPCs.
No induction of NSPC differentiation by a PARP inhibitor
While the PARP inhibitors suppressed NSPC neuro-
sphere formation, a small population of NSPCs attached 
to the bottom of the culture dish and extended projec-
tions, suggesting their differentiation into neurons or 
glial cells (Fig. 2a). We examined the phenotype of these 
cells by immunostaining for several cell type-specific 
markers: nestin for NSPCs, Tuj-1 for neurons, GFAP for 
astrocytes, and CNPase for oligodendrocytes. Tuj-1 or 
CNPase was undetectable after incubation with or with-
out PJ34 for 6  days, indicating no differentiation into 
neurons or oligodendrocytes, respectively, by this PARP 
inhibitor. Conversely, GFAP was detectable in a subpop-
ulation of NSPCs both in the presence and absence of 
PJ34, indicating that NSPCs could be differentiated into 
astrocytes under the present experimental conditions 
regardless of their exposure to this PARP inhibitor. The 
ratio of nestin-positive cells appeared not to be changed 
by PJ34, suggesting no effects of this PARP inhibitor on 
NSPC differentiation. These morphological changes 
were supported by quantitative mRNA analysis of cell 
type-specific markers (Fig.  2b). Among these markers, 
GFAP was only upregulated by a few fold after the addi-
tion of 20 μM PJ34. Conversely, the expression of GFAP 
increased by more than 600-fold after in vitro differentia-
tion of NSPCs into astrocytes. Most of the cells stopped 
proliferating and became apoptotic, while only a small 
number of cells, which attached to the bottom of the 
dishes, morphologically changed and extended projec-
tions. It appears that the cells that attached, or survived, 
differentiated into astrocytes, which likely caused a weak 
but significant upregulation of GFAP mRNA.
Suppression of cell cycle progression by a PARP inhibitor
We then assessed cell cycle progression in NSPCs by 
thymidine incorporation. S phase cells were obtained by 
using a double thymidine block that arrests the cells at 
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the G1/S boundary. The removal of thymidine by replace-
ment with normal medium, with or without the PARP 
inhibitor PJ34, induced the onset of the S phase. Every 
2 h from the onset of DNA synthesis, the cell cycle was 
analyzed by flow cytometry (Fig.  3). The proportion of 
cells in the G2/M phase reached the maximum value at 
6 h from the onset of the S phase in the absence of PJ34, 
while it took 8 h in the presence of PJ34. The peak of the 
proportion of cells in the G1 phase occurred after 14 or 
10 h with or without PJ34, respectively. These results sug-
gest that treatment with PJ34 suppressed cell cycle pro-
gression in NSPCs at the S phase and/or G2/M phase.
Induction of apoptosis in NSPCs by PARP inhibitors
The suppression of cell viability led us to examine 
whether the PARP inhibitors induce cell death, either 
necrosis or apoptosis, in NSPCs. Nuclear staining with 
Hoechst 33258 showed an intact or chromatin-con-
densed apoptotic pattern. Apoptotic cells prevailed after 
exposure to the PARP inhibitors (PJ34, DHIQ, or 3AB) in 
a concentration-dependent manner (Fig. 4a).
The pattern of cell death was then analyzed by the use 
of flow cytometry with APC-conjugated Annexin-V and 
7-AAD. Annexin-V has high affinity for phosphatidylser-
ine that is translocated from the inner to the outer leaflet 
of the plasma membrane during apoptosis. The cell mem-
brane of live cells is impenetrable to 7-AAD, but 7-AAD 
readily permeates and stains dead cells. Annexin-V(+)/7-
AAD(−) cells were considered to be at the early stage of 
apoptosis, whereas Annexin-V(+)/7-AAD(+) cells could 
be either necrotic or apoptotic at a later stage. Treatment 
with PJ34 significantly increased the proportion of apop-
totic Annexin-V(+)/7-AAD(−) cells by 27% compared 
to 12% in the control cells and decreased that of intact 
Annexin-V(−)/7-AAD(−) cells by 71% compared to 87% 
in the control cells (Fig. 4b).
Changes of mRNA expression profiles in the p53 signaling 
pathway by PARP inhibitors
In order to identify the causative genes that are involved 
in the pathway leading to the suppression of cell cycle 
progression and induction of apoptosis, microarray anal-
yses were carried out. The mRNA expression profiles 
in NSPCs were compared between cells in the presence 
and absence of PJ34. We found 142 genes upregulated 
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Fig. 1 Suppression of neurosphere formation and cell viability of NSPCs by PARP inhibitors. a Multiple neurospheres were detectable after a 2‑day 
incubation of NSPCs without a PARP inhibitor (control), while the number and size of neurospheres were much smaller in the presence of a PARP 
inhibitor (PJ34, DHIQ, or 3AB) in a dose‑dependent manner. b Cell viability was determined by the MTS assay. The MTS‑reduction activity of NSPCs 
was suppressed by the addition of a PARP inhibitor. Data shown in (b) are expressed as the ratio of the mean value of the control (vehicle alone) at 
time 0 (before incubation). Data represent the mean value ± SEM (n = 3). †p < 0.01 by comparison against control using one‑way ANOVA followed 
by Tukey’s post hoc test
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Fig. 2 No induction of differentiation of NSPCs into neurons or glial cells by a PARP inhibitor. a The cells were triple‑stained with Hoechst 33258 
(nuclear staining), anti‑nestin antibody (for NSPCs), and a cell‑specific antibody: anti‑Tuj‑1 antibody (for neurons), anti‑GFAP antibody (for astro‑
cytes), or anti‑CNPase antibody (for oligodendrocytes). Although the morphology of NSPCs was changed considerably after the addition of PJ34, 
the pattern of immunostaining was not changed. Differential interference contrast (DIC) images were on the left side. The positive controls for the 
antibodies used here are shown in the small images. b Quantitative mRNA analyses at 24 h after the addition of PJ34 (shown in the upper row) or 
6 days after withdrawal of the growth factors EGF and FGF for differentiation into astrocytes (shown in the lower row) were performed for cell type‑
specific markers: Tuj‑1 for neurons, nestin for NSPCs, GFAP for astrocytes, and CNPase for oligodendrocytes. Among these markers, GFAP was only 
upregulated by a few fold after the addition of 20 μM PJ34, while the expression of GFAP increased by more than 600‑fold after in vitro differentia‑
tion of NSPCs into astrocytes. Data shown in (b) are expressed as the ratio of the mean value of the control (vehicle alone). Data represent the mean 
value ± SEM (n = 3).*p < 0.05 (in the upper row) by comparison against control using one‑way ANOVA followed by Tukey’s post hoc test. †p < 0.01 
and §p < 0.001 (in the lower row) by comparison against control using Student’s t test. Scale bars in (a), 100μm
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a twofold change (p  <  0.05). In addition, several genes 
related to the p53 signaling pathway were significantly 
upregulated after the addition of PJ34, as shown by dif-
ferential expression analysis (p value  =  2.02E−8 and 
q value  =  8.48E−7) (Table  2; Fig.  5a). The upregula-
tion of Cdkn1a (p21), which plays a critical role in the 
control of the cell cycle, was more than twofold in the 







































































Fig. 3 Suppression of cell cycle progression of NSPCs by PJ34. Progression of the cell cycle with or without PJ34 was analyzed by thymidine incor‑
poration, followed by flow cytometry. The ratios of cells in the G1, S, and G2/M phases are illustrated every 2 h after the onset of the S phase. The 
results of flow cytometry at the peak of the G2/M or G1 phase are shown. Data represent the mean value ± SEM (n = 3)
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leading to apoptosis, including Fas (Fas), Pidd (PIDD; 
p53-induced death domain protein), Pmaip1 (Noxa), and 
Bbc3 (PUMA; p53 upregulated modulator of apoptosis), 
were also upregulated by more than 2-fold. Furthermore, 
Ccng1 (cyclin G1), which is involved in p53 negative 
feedback, was also upregulated. These results from the 
microarray analyses were confirmed by RT-PCR (Fig. 5b), 
indicating that PJ34 and also the other PARP inhibitors, 
DHIQ and 3AB, activate the two pathways downstream 
of p53: one pathway leads to cell cycle arrest through 
the activation of p21, while the other induces apopto-
sis by some apoptosis-related factors. Interestingly, the 
RT-PCR results demonstrated that the amount of p53 
mRNA in NSPCs was not changed by the PARP inhibi-
tors, whereas p53 protein was increased by the PARP 
inhibitors (Fig. 5c). This inconsistency indicated that the 
increase of p53 protein was not due to the overexpres-
sion of Trp53 (p53), but to the suppression of p53 pro-
tein degradation. In this context, the phosphorylation of 
p53 at Ser 18, which inhibits the binding of Mdm2 and 
stabilizes p53 protein, was found to be increased by the 
PARP inhibitors. The amount of p21 protein was defi-
nitely increased by the PARP inhibitors, which is con-
sistent with the upregulation of p21 mRNA expression. 
Furthermore, activation of the p53 signaling pathway to 
apoptosis resulted in the cleavage of pro-caspase-3.
In order to clarify which member of the PARP family is 
responsible for these effects of PJ34 on NSPCs, we used 
quantitative mRNA analysis to evaluate the effects of the 
inhibitors DR2313 and UPF1069, which are specific for 
PARP-1 and PARP-2, respectively (Fig. 5d). DR2313 upreg-

























Fig. 4 Induction of apoptosis in NSPCs by PARP inhibitors. a NSPCs were stained with Hoechst 33258 after a 24‑h incubation with the PARP inhibi‑
tors. Cells with condensed chromatin, which is indicative of apoptosis, were detectable after the addition of PJ34, DHIQ, or 3AB. The ratio of apop‑
totic cells increased in a dose‑dependent manner. b The rate of Annexin‑V‑positive cells after the addition of 20 μM PJ34 was analyzed by the use 
of flow cytometry staining with APC‑conjugated Annexin‑V and 7‑AAD. Data represent the mean value ± SEM (n = 6). ‡p < 0.005 by comparison 
against control using Student’s t test. Scale bars in (a), 20μm
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way as PJ34, while UPF1069 did not change the expres-
sion of these genes, except Bbc3 (PUMA). These findings 
confirmed PARP-1, but not PARP-2, as a target enzyme of 
PJ34 for its effects on the p53 signaling pathway in NSPCs.
Effects of PARP‑1 or PARP‑2 knockdown on the p53 
signaling pathway in NSPCs
We then carried out silencing of Parp1 or Parp2 by infec-
tion with shRNA-expressing lentiviruses. Parp1 or Parp2 
shRNA reduced the expression of the target gene to approx-
imately 10% compared with control shRNA (Fig. 6a). Genes 
in the p53 signaling pathway were upregulated by the sup-
pression of Parp1 expression, but not by Parp2 suppression 
(Fig. 6b). These findings were consistent with those obtained 
in the inhibitor experiments, and indicate that PARP-1, but 
not PARP-2, regulates the functions of p53 in NSPCs.
Activation of p53 by PARP inhibitors
The induction of apoptosis by the PARP inhibitors was 
demonstrated again by the detection of cleaved caspase 
fragments (Fig.  7a). One of the effector caspases, cas-
pase-3, was activated, as revealed by the detection of the 
cleaved fragment (p17) of pro-caspase-3. Among the ini-
tiator caspases, caspase-8 and caspase-9 were also dem-
onstrated to be activated by the detection of the cleaved 
fragments of the pro-caspases p43/p41/p18 and p37, 
respectively, although the band density of p37 was low.
The increased amount of total p53 and its phosphoryl-
ated form after the addition of PJ34 was revealed by immu-
nostaining with antibodies against p53 and phosphorylated 
p53 (Ser18), respectively (Fig.  7b). Furthermore, NSPCs 
contained much higher levels of PARP-1 protein than MEFs 
and this enzyme was constitutively activated, as revealed by 
its automodification, in NSPCs (Fig. 7c). The 89-kDa frag-
ment of PARP-1, which is generated by its cleavage by acti-
vated caspase-3, was also detectable. The increase of p53 
protein and its phosphorylation in the presence of PJ34 
were observed in NSPCs, but not in MEFs.
Effects of a PARP inhibitor on Trp53+/− and Trp53−/− NSPCs
In order to confirm a key role for p53 in the process under 
the regulation of poly(ADP-ribosyl)ation, we exam-
ined the effects of a PARP inhibitor on Trp53−/− as well 
as Trp53+/− NSPCs. PARP inhibition by PJ34 increased 
both total and phosphorylated p53 levels in wild-type 
and Trp53+/− NSPCs (Fig. 8a). Trp53−/− NSPCs formed 
larger neurospheres than Trp53+/− NSPCs, while 
Trp53+/− NSPCs generated a larger number of neuro-
spheres than wild-type NSPCs (Fig. 8b). After incubation 
with 10 μM or 20 μM PJ34 for 2 days, only a few neuro-
spheres were observed in wild-type NSPCs. In Trp53+/− 
NSPCs, neurospheres were still abundant in the presence 
of PJ34 at 10  μM, but not at 20  μM, although the neu-
rospheres became smaller. Remarkably, even at a concen-
tration of 20 μM, a substantial number of neurospheres 
were still present in Trp53 −/− NSPCs.
Cell viability was evaluated by measuring MTS-reduc-
ing activity. It should be noted that Trp53−/− NSPCs 
showed higher activity than wild-type or Trp53+/− NSPCs 
in the absence of PJ34 (Fig.  8c). After the addition of 
10  μM or 20  μM PJ34, the MTS-reducing activity of 
wild-type NSPCs was decreased. PJ34 also decreased the 
Table 2 Statistically significant changed categories (control vs. PJ34 in wild-type or Trp53−/−)
n/a indicates all categories’ p-values was more than 1E−04
Gene name Product Probe name Fold change p value q value
142 genes were up‑regulated by PJ34 in wild‑type NSPCs
 p53 signaling pathway
Bbc3 PUMA (BCL2 binding component 3) A_51_P248122 2.82 0.0136 0.0026
Ccng1 Cyclin G1 A_52_P612803 2.46 0.0240 0.0028
Cdkn1a p21 (cyclin‑dependent kinase inhibitor 1A) A_51_P363947 2.99 0.0082 0.0023
Fas Fas (TNF receptor superfamily member 6) A_55_P2091676 3.50 0.0053 0.0018
Lrdd PIDD (p53 induced death domain protein 1) A_55_P2085485 2.24 0.0215 0.0028
Perp PERP (p53 apoptosis effector) A_51_P317941 5.03 0.0028 0.0016
Pmaip1 Noxa (phorbol‑12‑myristate‑13‑acetate‑induced protein 1) A_51_P477121 3.80 0.0144 0.0026
Tnfrsf10b DR5 (tumor necrosis factor receptor superfamily, member 10b) A_55_P2027836 3.23 0.0295 0.0029
83 genes were down‑regulated by PJ34 in wild‑type NSPCs
 n/a
121 genes were up‑regulated by PJ34 in Trp53−/− NSPCs
 n/a
166 genes were down‑regulated by PJ34 in Trp53−/− NSPCs
 n/a




Fig. 5 Change of mRNA expression profiles in the p53 signaling pathway. a The mRNA expression profiles were generated by microarray analysis. 
The genes, the expression level of which increased more than 2‑fold after PARP inhibition, are indicated as a black box in the p53 signaling pathway 
published by the KEGG database. b The mRNA expression profiles shown in (a) were confirmed by RT‑PCR. Several genes downstream to Trp53 
(p53) were upregulated after PARP inhibition, whereas Trp53 itself was constant regardless of the presence of the PARP inhibitors. c Changes in the 
levels of p53 and phosphorylated p53 by the PARP inhibitors (PJ34, DHIQ, or 3AB) were observed in NSPCs. p21 protein as well as p21 mRNA, as 
shown in (b), were upregulated by all of the PARP inhibitors. Cleaved fragment of caspase‑3 at Asp 175 (p17), which is a marker of apoptosis, was 
also increased by PARP inhibition. d Quantitative mRNA analyses after the addition of PJ34, DR2313 (PARP‑1‑specific inhibitor), or UPF1069 (PARP‑
2‑specific inhibitor) were performed for the genes in the p53 signaling pathway. DR2313 as well as PJ34 upregulated the genes in the p53 signaling 
pathway, while UPF1069 did not change the expression of these genes, except Bbc3 (PUMA). Data shown in (d) are expressed as the ratio of the 
mean value of the control (vehicle alone). Data represent the mean value ± SEM (n = 3). *p < 0.05 by comparison against control using one‑way 
ANOVA followed by Tukey’s post hoc test
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MTS-reducing activity of Trp53+/− NSPCs at a concen-
tration of 20 μM, but not 10 μM, whereas that of Trp53−/− 
NSPCs was increased even after the addition of PJ34. 
These results clearly indicate that the effect of the PARP 
inhibitor PJ34 on the viability of NSPCs is mediated by 
p53.
In order to confirm the mRNA expression profiles in 
Trp53−/− NSPCs, mRNA levels were compared between 
the cells in the presence and absence of 20 μM PJ34 by 
microarray analyses. 121 genes were upregulated by and 
166 genes were downregulated by PJ34. However, there 
was no significantly changed category (Table 2).
Poly(ADP‑ribosyl)ation of ATM and ATR
As demonstrated by the experiments using Trp53−/− 
NSPCs, p53 plays a key role in the regulation of cell viability 
by the PARP inhibitors. We then examined the molecular 
mechanism of p53 activation by the PARP inhibitors. We 
performed a pull-down assay using poly-ADP-ribose affin-
ity resin, but were unable to isolate poly(ADP-ribosyl)ated 
p53 (Fig. 9a). An immunoprecipitation study using an anti-
p53 antibody showed the increased quantity of p53 protein 
after exposure to the PARP inhibitor PJ34, while poly(ADP-
ribosyl)ation of p53 was undetectable.
As both ATM and ATR regulate the stability and acti-
vation of p53 by phosphorylation at Ser18 [40], we exam-
ined whether PARP inhibition affects these 2 serine/
threonine protein kinases. We performed a pull-down 
assay with poly-ADP-ribose affinity resin, and detected 
both ATM and ATR at their expected sizes using spe-
cific antibodies (Fig. 9b). Certainly, the addition of PJ34 
inhibited the isolation of both kinases by poly-ADP-
ribose affinity resin. Poly(ADP-ribosyl)ation of these two 
kinases was confirmed by immunoprecipitation with 
an anti-ATM or anti-ATR antibody followed by detec-
tion with an anti-poly(ADP-ribose) antibody (Fig.  9c). 
Together with the finding of PARP-1 activation in NSPCs 
(see Fig. 9c), both ATM and ATR were found to be con-
stitutively poly(ADP-ribosyl)ated in these cells.
Discussion
NSPCs are localized in specific areas in the adult brain such 
as the subgranular zone of the dentate gyrus of the hip-
pocampus and subventricular area of the lateral ventricles 
[13, 14]. Once the brain is damaged by ischemia, NSPCs are 
activated and move to the infarct area [16]. Previously, we 
reported that PARP inhibitors could be a good therapeutic 
intervention for ischemic brain disorders through inhibi-
tion of apoptosis as well as necrosis of the affected neurons 
[9]. Lacza et al. [41] reported an improvement of the effec-
tiveness of neural stem cell transplantation through the 
suppression of the ONOO−–PARP activation cascade by 
PARP inhibitor. However, administration of PARP inhibi-
tors might influence NSPCs in the brain. In the present 
study, we demonstrated two types of effects of PARP inhib-
itors on NSPCs: suppression of cell cycle progression and 
induction of apoptosis. From a therapeutic point of view, 
these effects should be taken into consideration to deter-
mine the appropriate doses of PARP inhibitors.
The key molecule underlying these effects of the PARP 
inhibitors was proven to be p53, which restricts cellular 
growth by inducing cell cycle arrest (at the G1 and/or G2 
phase) or apoptosis [42, 43]. Several factors that influence 
the decision between the two types of effect include the 
expression level of p53, the type of stress signal, and cell 
type. Under our experimental conditions for NSPCs, where 
the cells were not exposed to specific stresses, the expres-
sion level of p53 was consistent and its phosphorylation, or 





























































































































































Fig. 6 Effects of PARP‑1 or PARP‑2 knockdown on the p53 signaling 
pathway in NSPCs. Quantitative mRNA analyses after silencing Parp1 
or Parp2 by shRNA‑expressing lentivirus were performed for Parp1 
and Parp2 (a) and the genes in the p53 signaling pathway (b). Genes 
in the p53 signaling pathway were upregulated by the suppression of 
Parp1 expression, but not by Parp2 suppression. Data shown in (a, b) 
are expressed as the ratio of the mean value of the sh Control group. 
Data represent the mean value ± SEM (n = 3). †p < 0.01, ‡p < 0.005, 
and §p < 0.001 by comparison against control using Student’s t test
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inhibitors, phosphorylation of p53 at Ser18 was enhanced, 
followed by the upregulation of p21, which is a potent cyc-
lin-dependent kinase inhibitor that functions as a regulator 
of cell cycle progression at the G1 and S phase [44].
The PARP inhibitor PJ34 also upregulated other 
p53-dependent factors in the pathways to apoptosis, i.e., 
Fas, PIDD, DR5, and PERP in the extrinsic apoptotic 
pathway and Noxa and PUMA in the intrinsic apoptotic 
pathway [45]. The extrinsic pathway is mediated by par-
ticular death receptors that are members of the tumor 
necrosis factor receptor family, including Fas, DR5, and 
PERP, whose activation induces the formation of the 
death-inducing-signaling-complex, and then activation 
of the caspase cascade, including caspase-8 and cas-
pase-3. In our study, both caspases were definitely acti-
vated after PARP inhibition, as revealed by the detection 
of the cleaved fragments of pro-caspases.
The intrinsic apoptotic pathway is activated in response 
to DNA damage and results in mitochondrial depolariza-
tion and release of cytochrome c into the cytoplasm [45]. 
Cytochrome c forms a complex “apoptosome” together 
with apoptotic protease-activating factor 1 and pro-cas-
pase-9, followed by the activation of caspase-9 and then 































Fig. 7 Higher amounts of p53 protein and phosphorylated p53 in NSPCs after PARP inhibition. a Cleaved fragments of caspase‑3 (p17) and cas‑
pase‑8 (p43/p41/p18) were clearly detectable by western blotting with specific antibodies. The cleaved fragment of pro‑caspase‑9 (p37) was also 
detectable, although the band density of this fragment was low. b Phase‑contrast images were shown on the top. Higher amounts of p53 protein 
and phosphorylated p53 in NSPCs after PARP inhibition were also revealed by immunocytochemistry. Representative images from 4 separate 
experiments are shown. c Western blot analysis demonstrated that PARP‑1 was abundant and activated in NSPCs in contrast to MEFs. Amounts of 
p53 protein and phosphorylated p53 at Ser 18 were remarkably increased by PJ34. Scale bars in (b), 20μm
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[46]. PJ34 induces the transcription of PUMA, also known 
as Bcl-2-binding component 3 (BBC3), which interacts with 
antiapoptotic Bcl-2 family members, leading to the forma-
tion of the free-type of Bax and/or Bak, which are then able 
to signal apoptosis to the mitochondria [47]. Intriguingly, a 
balance between PUMA and p21 reportedly determines the 
onset of cell cycle arrest, or death, in response to exogenous 
p53 expression. In our study, PJ34 also upregulated another 
p53 target gene, Noxa, which encodes a BH3-only protein 
and hence is considered to induce p53-mediated apoptosis 
in a manner similar to PUMA [45]. Thus, it appears that, 
in response to PARP inhibition, p53 activates the intrinsic 
apoptotic pathway by inducing the expression of at least 
two Bcl-2 pro-apoptotic family members including PUMA 
and Noxa. The fragment of pro-caspase-9, however, was 
only slightly detectable, indicating that the involvement of 
the intrinsic apoptotic pathway was limited.
The interaction of p53 with PARP-1 or poly(ADP-ribo-
syl)ation of p53 has been proposed by several investiga-
tors [48–51]. The DNA-binding domain of p53 contains 
some poly(ADP-ribose)-binding sites, which could inter-
fere with its site-specific DNA-binding activity and 
block its transcriptional function [48, 49]. Alternatively, 
poly(ADP-ribose) could induce the upregulation of p53 
by protecting the protein from proteolytic degrada-
tion. One of the poly(ADP-ribose) binding sites in p53 is 
located near a proteolytic cleavage site, which suggests 
that polymer binding might protect this sequence from 
proteolysis [51]. Interestingly, Kanai et  al. [52] reported 
that poly(ADP-ribosyl)ation of p53 blocked the interac-
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Fig. 8 Effects of PJ34 on neurosphere formation and cell viability of Trp53+/− and Trp53−/− NSPCs. a Western blot analysis demonstrated that the 
amounts of p53 protein and phosphorylated p53 at Ser18 were increased by PJ34 in Trp53+/− NSPCs as well as wild‑type NSPCs. Automodifica‑
tion of PARP‑1 was detectable irrespective of Trp53 genotype. b Neurospheres were detectable in wild‑type NSPCs after a 2‑day incubation in the 
absence of PJ34, but were scarcely detectable with 10 or 20 μM PJ34. In contrast, neurospheres were still detectable with 10 μM PJ34 in Trp53+/− 
NSPCs, and with 10 or 20 μM PJ34 in Trp53−/− NSPCs. c The increase of MTS‑reduction activity of wild‑type NSPCs was suppressed by 10 or 20 μM 
PJ34. No suppressive effect of PJ34 was observed in Trp53−/− NSPCs. Data represent the mean value ± SEM (n = 3). *p < 0.05 and †p < 0.01 by one‑
way ANOVA followed by Tukey’s post hoc test. Scale bars in (b), 50μm
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followed by the accumulation of p53 in the nucleus and 
activation of its transactivation function. These find-
ings are not necessarily consistent with ours in which 
poly(ADP-ribosyl)ated p53 was undetectable. This incon-
sistency may be due to differences in the type of cell and 
stress utilized.
Some kinases, such as ATM and ATR, are reportedly 
responsible for the phosphorylation of p53 at Ser15 
(human), i.e., Ser18 (mouse) [53, 54]. Phosphorylation 
at this site, as observed in our study, and also at Ser20 
(human), could inhibit the binding of the p53-degrading 
enzyme Mdm2 (Hdm2 in humans), resulting in the sta-
bilization of p53 [53]. Watanabe et al. [55] reported that 
after the induction of DNA double-strand breaks (DSBs) 
in MEFs by neocarzinostatin, PARP-1 negatively regu-
lated ATM kinase activity and inhibited phosphoryla-
tion of p53 at Ser18. Kedar et al. [56] demonstrated that 
ATR interacted with PARP-1 after treatment with methyl 
methanesulfonate, but this interaction was not detectable 
after PARP inhibition. Under conditions of PARP inhibi-
tion in MEF culture, the cells accumulated in the S phase, 
probably due to ATR activation. They also demonstrated 
that ATR is a substrate for poly(ADP-ribosyl)ation by 
PARP-1 in  vitro. These results suggest that poly(ADP-
ribosyl)ation of ATM and/or ATR after DSBs inactivates 
these kinases, leading to the inhibition of p53 phos-
phorylation. In our experiments using NSPCs without 
induction of DSBs, both ATM and ATR were poly(ADP-
ribosyl)ated or inactivated. The PARP inhibitors removed 
this modification and activated these kinases, resulting in 
increased phosphorylation of p53 at Ser18 and stabiliza-
tion of this protein.
PARPs constitute a large family of as many as 17 pro-
teins [1], and PARP-1 is an abundant nuclear protein and 
the founding member of the PARP family. As poly(ADP-
ribose) is mainly synthesized by PARP-1 after DNA 
damage, PARP-2 was initially thought to be a “backup 
of PARP-1.” On the contrary, Parp-2−/− mice exhibit 
impaired spermatogenesis [57], adipogenesis [58], and 
thymocyte survival [59], although Parp-1−/− mice dif-
ferentiate normally in these processes. Thus, PARP-2 
might have different targets from PARP-1, suggesting 
that they could play specific biological functions. Inter-
estingly, PARP-1/PARP-2 double knockout mice, which 
lack poly(ADP-ribosyl)ation, are embryonic lethal [60]. 
Therefore, both PARP-1 and PARP-2 are thought to con-
duct critical roles in embryonic development. Our study 
using specific inhibitors and also shRNAs suggested 
that PARP-1, but not PARP-2, plays a role in the regula-
tion of p53 functions. In this study, PUMA, a pro-apop-
totic  protein located in the p53-signaling pathway, was 
upregulated after treatment with the PARP-2-specific 
inhibitor UPF1069, which may be due to an unknown 
function of UPF1069 besides PARP-2-specific inhibi-
tion. This possibility should be investigated in further 
experiments.
Recent reports have provided evidence that intracel-
lular programs, including epigenetic modifications, 
transcription factors, and extracellular signals, such 
as various cytokines, are involved in the induction of 
NSPC differentiation [61]. PARP1 as well as Tet2 are 
responsible for epigenetic modifications during the 
reprogramming process [62]. PARP-1 expression was 
found to be enhanced both in embryonic stem cells 
and induced pluripotent stem (iPS) cells. PARP-1 acti-
vation plays a key role both in the induction of iPS cells 
and the maintenance of pluripotency [63]. Interest-
ingly, several groups have reported that p53 suppresses 
iPS cell generation and that its molecular mechanism 

















































Fig. 9 Poly(ADP‑ribosyl)ation of ATM and ATR, but not p53. a 
Poly(ADP‑ribosyl)ated proteins were isolated from cell lysates by 
highly specific macrodomain poly(ADP‑ribose) affinity resin. The resin‑
bound proteins were eluted and analyzed by western blotting with 
an anti‑p53 antibody. Immunoprecipitation was carried out using an 
anti‑p53 antibody. The resulting immunocomplexes were subjected 
to western blot analysis with anti‑p53 and anti‑poly(ADP‑ribose) anti‑
bodies. Poly(ADP‑ribosyl)ated p53 was undetectable irrespective of 
PARP inhibition. b The same membrane on which the proteins eluted 
from poly(ADP‑ribose) affinity resin were transferred was analyzed by 
western blotting with anti‑ATM and anti‑ATR antibodies, resulting in 
the detection of ATM and ATR. c Immunoprecipitation was performed 
using an anti‑ATM or anti‑ATR antibody. Immunocomplexes were 
subjected to western blot analysis with an anti‑ATM or anti‑ATR anti‑
body as well as an anti‑poly(ADP‑ribose) antibody. Poly(ADP‑ribosyl)
ated ATM and ATR were detectable in the absence of PJ34
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resulting in a restriction of cell cycling, and induction 
of apoptosis [27, 28, 64]. On the basis of these find-
ings and our predictive model, for the maintenance 
of NSPC multipotency as well as pluripotency of iPS 
cells, suppression of p53 function by PARP-1 might be 
required.
Conclusions
Our results indicate the possibility that PARP-1 acti-
vation or poly(ADP-ribosyl)ation contributes to the 
proliferation of NSPCs by advancing the cell cycle and 
suppressing apoptosis in addition to epigenetic modifi-
cations. Inactivation of ATM/ATR and the p53 pathway 
is suggested to be a mechanism that explains how PARP 
promotes proliferation and thus maintains NSPC multi-
potency (Fig. 10).
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